<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845217</url>
  </required_header>
  <id_info>
    <org_study_id>21.0286</org_study_id>
    <nct_id>NCT04845217</nct_id>
  </id_info>
  <brief_title>Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome</brief_title>
  <official_title>Efficacy of Peppermint Oil in a Randomized, Single-Blind, Placebo Controlled Trial in Women With Interstitial Cystitis/Bladder Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrative Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the use of peppermint oil as a treatment for&#xD;
      Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all participants will complete&#xD;
      validated IC/BPS symptom questionnaires for baseline screening. Once participants meet&#xD;
      eligibility requirements and give written informed consent they will be randomized in a 1:1&#xD;
      ratio to peppermint oil (200mg TID) or placebo (also TID). Participants will complete&#xD;
      validated IC/BPS questionnaires and follow up surveys over 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized in a 1:1 ratio to the intervention or placebo arm. Allocation concealment will be in place to ensure the individual enrolling the subject into the study has no a priori knowledge of group assignment. Block randomization will occur with randomly mixed block sizes of 4, 6, and 8 using the randomization list generator at www.sealedenvelope.com. Randomization information will be kept confidential and only available to study personnel.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The peppermint-oil and placebo treatments will be kept in a locked and secured area of the office, in a room not used for patient care. The bottles will be de-identified, with labels detailing the specific instructions for how to take the soft gels and the number in each bottle. Each group will be instructed to take one soft gel three times daily.&#xD;
The peppermint oil and placebo medications will be distributed by the research team. The manufacturer label will be covered up/removed and a study label stating the use of a study medication will be used to maintain patient blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>O'Leary/Sant questionnaire scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participant responses to the O'Leary/Sant questionnaire assessing IC/BPS symptoms will be compared at baseline and after starting treatment with peppermint oil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Pain and Urgency/Frequency questionnaire scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participant responses to the Pelvic Pain and Urgency/Frequency questionnaire assessing IC/BPS symptoms will be compared at baseline and after starting treatment with peppermint oil.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine pH</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in urine pH on urine dipstick from clinically indicated lab collections at the time of office visits during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urinary tract infections (UTIs)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Culture proven UTIs during the study period (&gt;100,000 CFU of a single pathogen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional IC/BPS Treatments received</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number and type of additional IC/BPS each participant undergoes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>Peppermint Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intervention (peppermint oil) arm will receive soft gels of enteric-coated peppermint oil (0.2mL=200mg). The enteric coated peppermint oil soft gel utilized in this study is Peptogest Peppermint Oil from Schwabe North America (Nature's Way Brand).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coconut Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in the placebo (coconut oil) arm will receive soft gels of enteric coated coconut oil. The enteric coated coconut oil soft gel utilized in this study is Coconut Oil from Schwabe North America (Nature's Way Brand).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peppermint oil</intervention_name>
    <description>Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.</description>
    <arm_group_label>Peppermint Oil</arm_group_label>
    <other_name>Peptogest Peppermint Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coconut Oil</intervention_name>
    <description>Enteric coated coconut oil taken by mouth three times daily for 8 weeks</description>
    <arm_group_label>Coconut Oil</arm_group_label>
    <other_name>Coconut Oil Pure Extra Virgin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ages 18-65 years old&#xD;
&#xD;
          -  Diagnosed with IC/BPS for at least one month prior to study enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Culture proven urinary tract infection within 1 month of randomization&#xD;
&#xD;
          -  Gross hematuria&#xD;
&#xD;
          -  Currently pregnant or breastfeeding&#xD;
&#xD;
          -  Unable to speak and read English&#xD;
&#xD;
          -  History of allergic reaction to peppermint, coconut or enteric coating&#xD;
&#xD;
          -  History of malabsorption syndrome&#xD;
&#xD;
          -  History of gastroparesis&#xD;
&#xD;
          -  History of gastric bypass surgery&#xD;
&#xD;
          -  History of gastrointestinal, genitourinary or pelvic cancer in the last 5 years&#xD;
&#xD;
          -  History of insulin dependent diabetes&#xD;
&#xD;
          -  History of active urinary stone disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Francis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Chair</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenna Warehime, DO</last_name>
    <phone>502-588-7660</phone>
    <email>jenna.warehime@louisville.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Springs Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Francis, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Sean Francis</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>interstitial cystitis</keyword>
  <keyword>bladder pain syndrome</keyword>
  <keyword>peppermint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peppermint oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

